
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences is poised for significant growth with its AI-powered ECG diagnostic solutions that have the potential to transform the healthcare industry by making ECGs a more valuable tool for detecting heart disease. The company's MyoVista cloud software platform and wavECG device, which are both in the final stages of FDA approval, offer a scalable revenue opportunity through installation fees, SaaS usage fees, and marketplace fees for AI-ECG algorithms. While dilution and execution challenges pose potential risks, the company's successful 510(k) submission for the MyoVista device and upcoming commercialization of MyoVista Insights demonstrate a strong potential for future success and we maintain our buy rating with a price target of $9.20.
Bears say
HeartSciences is decreasing its expenses and raising its EPS estimates for FY26 and FY27 due to lack of visibility on commercial revenues. Additionally, the company has begun phase 1 rollout of its MyoVista Insights cloud-platform and is aiming for FDA clearance in the first half of CY2026, which may contribute to potential future revenues. However, there is still a lack of clarity on the company's commercialization strategy and revenue potential.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares